Imatinib-acquired resistance related to the presence of secondary point mutations has become a frequent event in gastrointestinal stromal tumors. Here, transient transfection experiments with plasmids carrying two different KIT-acquired point mutations were performed along with immunoprecipitation of total protein extracts, derived from imatinib-treated and untreated cells. The molecular mechanics/Poisson Boltzmann surface area computational techniques were applied to study the interactions of the wild-type and mutated receptors with imatinib at the molecular level. Biochemical analyses showed KIT phosphorylation in cells transfected with vectors carrying the specific mutant genes. Imatinib treatment demonstrated that T670I was insensitive to the drug at all the applied concentrations, whereas V654A was inhibited by 6 lM of imatinib. The modeling of the mutated receptors revealed that both substitutions affect imatinib-binding site, but to a different extent: T670I substantially modifies the binding pocket, whereas V654A induces only relatively confined structural changes. We demonstrated that T670I and V654A cause indeed imatinib-acquired resistance and that the former is more resistant to imatinib than the latter. The application of molecular simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a molecular rationale for this type of drug resistance.
Imatinib-acquired resistance related to the presence of secondary point mutations has become a frequent event in gastrointestinal stromal tumors. Here, transient transfection experiments with plasmids carrying two different KIT-acquired point mutations were performed along with immunoprecipitation of total protein extracts, derived from imatinib-treated and untreated cells. The molecular mechanics/Poisson Boltzmann surface area computational techniques were applied to study the interactions of the wild-type and mutated receptors with imatinib at the molecular level. Biochemical analyses showed KIT phosphorylation in cells transfected with vectors carrying the specific mutant genes. Imatinib treatment demonstrated that T670I was insensitive to the drug at all the applied concentrations, whereas V654A was inhibited by 6 lM of imatinib. The modeling of the mutated receptors revealed that both substitutions affect imatinib-binding site, but to a different extent: T670I substantially modifies the binding pocket, whereas V654A induces only relatively confined structural changes. We demonstrated that T670I and V654A cause indeed imatinib-acquired resistance and that the former is more resistant to imatinib than the latter. The application of molecular simulations allowed us to quantify the interactions between the mutated receptors and imatinib, and to propose a molecular rationale for this type of drug resistance. Keywords: imatinib secondary resistance; gastrointestinal stromal tumors (GIST); molecular modeling Gastrointestinal stromal tumors (GIST) are the most common mesenchymal malignancies of the gastrointestinal tract and are characterized by the presence of constitutively activated KIT (CD117) or PDGFRA receptors. In both the receptors, the mechanism responsible for kinase activation is mainly represented by gain-of-function mutations, which always affect specific exons (Corless et al., 2004) . To date, several types of mutations have been described and the main mutational 'hot spot' is represented by c-Kit exon 11 (Corless et al., 2002; Heinrich et al., 2003) .
Imatinib mesylate (Glivect, Novartis, Basel, Switzerland) is an inhibitor of a number of tyrosine kinases including the intracellular kinase ABL, the growth factor receptors KIT, PDGFRb and a and ARG and their oncogenic activated forms. Imatinib competes with ATP for ATP-binding site of the kinase preventing the downstream signaling.
Recently, GIST cases showing acquired resistance to imatinib, that is, tumoral growth after an initial response, have been reported and molecularly analysed (Chen et al., 2004; Tamborini et al., 2004 Tamborini et al., , 2005 Antonescu et al., 2005; Debiec-Rychter et al., 2005; Wardelmann et al., 2005) . Although several mechanisms have been proposed to be responsible for this phenomenon, including KIT gene amplification, the emergence of additional point mutations appears to be the most frequent event. This suggests that imatinib secondary resistance in GIST may be an 'in expansion phenomenon' not yet fully investigated in terms of temporal development of the disease.
The secondary point mutations till now described always involve the kinase domain of the receptor and have been described in exons 13, 14 and 17 of c-Kit gene and in exon 18 of PDGFRA gene (Chen et al., 2004; Tamborini et al., 2004 Tamborini et al., , 2005 Antonescu et al., 2005; Debiec-Rychter et al., 2005; Wardelmann et al., 2005) . Their presence in the ATP pocket of the kinase suggests that imatinib is not able to inhibit the receptor efficiently, most likely because of a different tridimensional proteic structure of the ATP pocket induced by these additional mutations.
In this work, by means of biochemical assay on cells transfected with KIT mutants and treated with different doses of imatinib, we have demonstrated that two KIT mutations detected in three GIST patients with acquired resistance to imatinib are actually responsible for this phenomenon. The coupled molecular modeling simulations on the same mutated receptors allowed us to quantify the interactions between the mutated receptors and the drug, thus providing a molecular rationale for the modulation of the differences in drug resistance.
A series of patients surgically treated at the Istituto Nazionale per lo Studio e la Cura dei Tumori-Milan, all showing clinical/radiological evidence of progressing disease during imatinib treatment after an initial response, were investigated for the presence of KIT and PDGFRA gene mutations. A written informed consent was obtained from each subject.
The sequencing of the whole coding sequence of KIT revealed activating mutations in exon 11 in all of the patients. In three patients, characterized by the following exon 11 mutations (D557-558 in patient 1, V559A in patient 2 and W557G in patient 3), two different adjunctive point mutations in KIT gene were detected: one (in patient 1) (Tamborini et al., 2004) in exon 14 responsible for T670I substitution, threonine versus isoleucine, and one (in two different patients, 2 and 3, respectively) in exon 13 causing the V654A substitution, valine versus alanine . None of the patients revealed mutations affecting PDGFRA gene. and KIT/V654A). c-Kit mutants were constructed by means of site-directed mutagenesis using the Promega kit, and an expression vector carrying a wild-type c-Kit gene (kindly provided by Dr Yarden) was used as template. The mutant D559 was obtained by deleting base pairs 1696-1698 (GTT) in exon 11 of the wild-type gene; the T670I mutant was obtained by substituting the base C 2030 with T in exon 14; and the V654A mutant was obtained by substituting the base T1982 with a C in exon 13. All the plasmids were sequenced in order to verify the success of mutagenesis experiments. The transfected cells were incubated with imatinib at the indicated doses for 8 h. Protein extracts from the transfected cells were obtained by means of homogenization at 41C in lysis buffer (50 mM Hepes, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mM Na 4 P 2 O 7 and 100 mM NaF) supplemented with protease and phosphatase inhibitors (Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail 2, phenylmethylsulfonylfluoride, Sigma, St Louis, MO, USA). After lysing by means of frequent vortexing, the protein lysates were cleared by means of centrifugation at 13 000 r.p.m. at 41C for 30 min, and quantitated using the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Total protein extracts (1 mg) were immunoprecipitated using 360 ng of Ab-3 (K45) (Neomarkers, Fremont, CA, USA) monoclonal antibody directed against KIT receptor as described previously (Tamborini et al., 2004) ; the positive control was 500 mg of D559 cell line lysate. Both the mature (145 kDa) and partially glycosylated (125 kDa) forms of KIT receptor were detected. (b) Same as panel A, but using the KIT/D559/T670I and KIT/D559/TV654A mutants. T670I and V654A mutations were introduced into D559/KIT mutant. In these experiments, 500 mg of total protein extract was immunoprecipitated and used for Western blot analysis. Both KIT receptor isoforms (mature and partially glycosylated forms) were detected. Biochemical and molecular modeling analyses of two KIT mutants E Tamborini et al
The morphological and immunohistochemical analysis of the imatinib-insensitive tumors revealed highly cellulated tumoral samples with strong cytoplasmic CD117 positivity. Immunoprecipitation and Western blot experiments showed highly expressed and phosphorylated KIT receptors despite all of these patients being treated with imatinib (Tamborini et al., 2004 , and data not shown).
Imatinib mesylate activity on KIT mutants
In order to verify whether the amino-acidic changes caused by exons 14 and 13 mutations were actually responsible for the acquired resistance to imatinib, the T670I and the V654A mutations were introduced into the wild-type c-Kit cDNA contained in an expression vector. The resulting constructs, KIT/T670I and Figure 2 Molecular modeling of KIT/T670I mutant. The procedure applied in this work has been described in detail in our previous work (Pricl et al., 2005) . Accordingly, only a brief outline of the method is reported. All simulations were carried out using the Sander modulus of AMBER 7.0 (Case et al., 2000) and the Cornell et al. (1995) force field. The 1.60-Å -resolution coordinates of the kinase domain of KIT in complex with imatinib were obtained from the Brookhaven Protein Data Bank (PDB code 1T46) (Mol et al., 2004) , and used as the starting structure. All crystallographic water molecules were included, and the missing hydrogen atoms were added to the protein backbone and side chains with the Parse module of AMBER 7.0. All ionizable residues were considered in the standard ionization state at neutral pH. The missing force field parameters for the inhibitor were taken from our previous work (Pricl et al., 2005) . Mutations T670I and V654A were introduced into the wild-type structure of KIT/imatinib complex using the Biopolymer module of Insight II (v. 2001, Accerlys Inc., San Diego, CA, USA) by swapping the mutant residue into the specific site, according to a dedicated and well-validated procedure (Reyes and Kollman, 2000; Pricl et al., 2005) . To set up each resulting complex for the simulation, we adopted the following ansatz: first, each complex was immersed in a sphere of TIP3P water molecules (Jorgensen et al., 1983) . To achieve electroneutrality, a suitable number of counterions were added, in the positions of largest electrostatic potential, as determined by the module Cion within AMBER 7.0. All three systems (wild type, T670I and V654A KIT/imatinib complexes, respectively) were then minimized and equilibrated with the same protocol. Briefly, the energy of each complex was gradually minimized, followed by 40 ps of dynamics of the water molecules, to let the water relax around the solute. At the end of the relaxation process, all water molecules beyond the first hydration shell were removed. To reduce computational time to reasonable limits, all protein residues with any atom closer than 30 Å from the center of mass of the considered mutation were chosen to be flexible in the subsequent dynamic simulations. Subsequently, a spherical TIP3P water cap of radius equal to 30 Å was centered on imatinib in each corresponding complex, including the hydrating water molecules within the sphere resulting from the previous step. The new water cap was relaxed, followed by another gradual and global energy minimization of the entire system. Using separate solvent-solute Berendsen temperature coupling (Berendsen et al., 1984) , each system was heated up to 300 K in three stages. This gradual heating served to equilibrate the kinetic energy of the system, evenly distributing it among the many degrees of freedom. Each hydrated complex was then further equilibrated for 50 ps at 300 K, and we continued each simulation for the other 400 ps at 300 K, a time necessary for the estimation of the free energy of binding (vide infra). The molecular dynamics (MD) simulations were performed using an integration time step of 2 fs and by the application of the Shake algorithm (Ryckaert et al., 1977) . Long-range nonbonded interactions were truncated by using a dual cutoff of 12 and 30 Å . The simulations of the three complexes were performed on a cluster of Silicon Graphics Octane (single and dual processor R12K). All energetic analysis was carried out for only a single MD trajectory of each KIT/imatinib complex considered, with unbound protein and substrate snapshots taken from the snapshots of that trajectory. According to the so-called molecular mechanics/Poisson-Boltzmann surface area method (Gilson et al., 1987) , the binding free energy between imatinib and c-Kit can be calculated as follows:
where
DE MM denotes the sum of MM energies of the molecules, and can be further split into contributions from electrostatic (E EL ) and van der Waals (E vdW ) energies:
The terms in equation (3) were calculated by using the Carnal and Anal modules of AMBER 7.0. DG solv (see equation (2)) represents the solvation free energy. The polar solvation process (i.e., DG PB in equation (2)) is equivalent to the transfer of a protein from one medium with dielectric constant equal to that of the interior of the protein to another medium with dielectric constant equal to that of the exterior of the protein. This term yields a free energy because it corresponds to the work carried out to reversibly charge the solute, and it is a polarization free energy because the work goes to the polarization of the solvent. It was evaluated with the PoissonBoltzmann (PB) approach (Srinivasan et al., 1998) . The nonpolar solvation contribution to solvation (i.e., DG NP in equation (2)) includes cavity creation in water and van der Waals interactions between the modeled nonpolar protein and water molecules. This term can be imagined as transferring a nonpolar molecule with the shape of the protein from vacuum to water. It was calculated (Gilson et al., 1987) as
, b ¼ 0.92 kcal/mol and SASA is the solvent-accessible surface estimated with the MSMS program (Sanner et al., 1996) . Finally, the normal-mode analysis approach was followed to estimate the last parameter, that is, the change in solute entropy upon association -T DS (Wilson et al., 1995) . The free energy of binding difference DDG bind between wild-type and each c-Kit mutant and imatinib was calculated as KIT/V654A, were transiently expressed into COS1 cells. As positive control in the experiments, the KIT/D559 mutant, carrying the deletion of residue 559 and previously shown to respond to imatinib (Tamborini et al., 2004) , was used. Based on antiphosphotyrosine immunoblot analysis with cells treated with three different doses of the drug, KIT/T670I and KIT/V654A were clearly resistant to imatinib compared to the KIT/D559 imatinib-sensitive mutation. KIT/T670I appeared to be phopshorylated and thus insensitive to the drug at all the doses used, whereas KIT/V564A appeared to be totally inhibited at 6 mM of imatinib (Figure 1a, upper panel) .
As in all the patients, in whom these amino-acidic substitutions were present, the corresponding DNA mutations were on the same allele carrying also the activating exon 11 KIT mutation, we investigated the effect of their presence on an activated KIT receptor. Through a specific PCR reaction, we obtained a DNA fragment spanning a KIT cDNA region from exon 11 to 14. We subcloned it into pGEM vector, and the sequencing of several colonies revealed that on the same DNA fragment, both the mutations (exon 11 plus exon 13 or 14) were present.
We introduced therefore the T670I and the V654A mutations into the activated KIT/D559 mutant, previously shown to be inhibited by imatinib. The resulting KIT/D559/T670I and KIT/D559/V654A mutants were transiently expressed in COS1 cells. Western blot analysis showed that KIT/D559/T670I was resistant to imatinib at all the concentrations, whereas KIT/D559/ V654A appeared to be reduced at 3 mM and inhibited at the dose of 6 mM of imatinib (Figure 1b , lower panel).
Molecular modeling
Mutating T into I at position 670 in the ATP-binding site of the KIT kinase domain results in a calculated DDG bind for imatinib equal to -3.84 kcal/mol (Table 1) .
Both nonbonded interaction components of the free energy of binding strongly decrease in the presence of the mutated isoform (DDE MM ¼ À5.87 kcal/mol; Table 1 ). This markedly decreased affinity for this mutant with respect to imatinib might be ascribed to the molecular dimensions of the inhibitor, which are too big to result in a snug fit within the pocket formed at the Nand C-lobe interface of the inactive structure of the kinase. Indeed, the phenyl ring of imatinib packs too tightly between the aliphatic chains of D810, E640 and L644, whereas the piperazine ring makes no specific interactions with the protein and fits in a shallow pocket bounded by V643, C788, I789, H790, R791 and D810 ( Figure 2a) . As seen for the analogous mutation T315I in the ABL kinase domain (Pricl et al., 2005) , in a sort of a domino effect, the substitution of this single residue in this position induces several, sometimes substantial, modifications in the conformation of other residues, both belonging to the binding site and the surrounding areas, as a direct consequence of the different position assumed by imatinib in the binding site. The topical, stabilizing hydrogen bond between the aminopyridine nitrogen of imatinib and the side chain Og1 atom of the gatekeeper residue T670 does no longer exist, and is not replaced by any similar, favorable interaction (Figure 2b and c). Moreover, the greater molecular volume of isoleucine (I) side chain with respect to threonine (T) (73.0 versus 48.6 Å 3 , respectively) induces imatinib to assume a slightly modified position within the pocket (Figure 2b and c) , to alleviate sterical unfavorable interferences. From an electrostatic viewpoint, the T670I mutant protein is further penalized, as a nonpolar moiety, such as the isoleucine side chain, is surrounded by a strongly polar environment generated by three nitrogen atoms of imatinib (Figure 2c ). The universally conserved DGF motif, fundamental for the catalytic activity, is kept in the inhibited orientation in the wildtype KIT-imatinib complex, whereas it moves toward the productive state in the mutated complex. This is caused by the deleterious readjustment of the DGF motif, mainly owing to a steric clash of the inhibitor with the side chain of F810 (Figure 2d) . Finally, the active kinase structure is characterized by a critical salt link between a conserved C-helix D640 and K623 that orients the lysine side chain for interactions with the nucleotide phosphate (Mol et al., 2003) . This salt link, absent in the trajectory of the wild-type KIT/imatinib, is present in the corresponding molecular dynamics (MD) simulation of the T670I mutant/imatinib complex, with an average dynamic length of 2.8 Å .
Residue V654 is in KIT kinase domain 1, and is notably conserved among other kinases such as Abl, Src, Hck, Flt3 and PDGFR. Mutating V to A at position 654 in the ATP-binding domain of the KIT results in calculated DDG bind for imatinib of -1.52 kcal/ mol. Indeed, exchanging V to A decreases the degree of surface complementarity between KIT and the inhibitor, owing to the smaller A dimensions (Figure 3a and b) , which account for the most part of the nonbonded interactions (DDE vdW ¼ À1.08 kcal/mol and DDE MM ¼ À1.27 kcal/mol; Table 1 ). In contrast to that observed for the T670I mutation, in fact, both the electrostatic and solvation terms remain almost unaffected, as expected for a conservative substitution (Table 1) . We can conclude that this decrease in the binding affinity is substantially owing to the loss of packing interaction (i.e., cavity formation) in the native state of the alanine-containing variant (Figure 3c and d) . We can then estimate the destabilizing effect of cavity formation per one carbon (methyl group) atom. The V to A substitution removes two carbon atoms; the calculated DDG bind for V654A mutant disfavors the mutant by 1.52 kcal/mol, resulting in a destabilization of approximately 0.8 kcal/mol per carbon atom upon cavity formation. This estimate is in good agreement with the results of earlier experimental studies (Kellis et al., 1988; Eriksson et al., 1992; Pace et al., 1996; Loladze et al., 2002) and theoretical calculations (Nicholls et al., 1991; Lee, 1993; Lazaridis et al., 1995) . Replacing V with A at position 654 further reflects only in a slight alteration of some other imatinib contact points (E640, T670, C673 and F811) and some ATP-binding residues (K623 and E671). In particular, the readjustment of K623 results in a decreased interaction of this residue with E640 in C-helix (Figure 3e ). Finally, V654 is engaged in two stabilizing hydrogen bond interactions. The former involves the C ¼ O backbone group of V654 and the bridging water 956 on one side (ADL ¼ 2.85 Å ), and the same water molecule and the C ¼ O backbone group of G648 on the other (ADL ¼ 2.81 Å ). The second H-bond involves the NH backbone moiety of V654 and the backbone C ¼ O of I808, with an ADL of 3.03 Å . Interestingly, the same interactions are present in our MD trajectory of the (atom-colored stick-and-ball rendering) . (e) Details of the interaction of A654 and some imatinib contact points and ATP-binding residues. All residues are in stick rendering (color code: K623, pink; E640, green; A654, cyan; T670, purple; E671, orange; and C673, light blue). Imatinib is in atomcolored stick-and-ball rendering. C-helix is in gold ribbon rendering.
Biochemical and molecular modeling analyses of two KIT mutants E Tamborini et al A654 mutant, the former involving the same functional groups and water 1011 (ADL ¼ 2.90 and 2.83 Å , respectively), and the second being characterized by ADL ¼ 2.93 Å . As these H-bonds involve only backbone atoms of the residue at position 654, it is not surprising that the same two favorable interactions are preserved in our simulation of the A654 variant.
In this work, we report the biochemical characterization coupled with the molecular modeling of two c-Kit mutations, responsible for T670I and V654A substitutions, respectively, detected in three different patients with clinical and radiological symptoms of progressing disease during imatinib treatment. At disease onset, these patients displayed activating mutations affecting c-Kit exon 11 (D557-558, V559A and W557G, respectively), alterations associated to a significantly high response rate to imatinib (Corless et al., 2004) .
By treating transfected COS cells expressing mutated KIT receptors carrying these substitutions (KIT/T670I, KIT/D559/T670I, KIT/V654A and KIT/D559/V654A) with different doses of imatinib, we demonstrated that the presence of I (isoleucine) at position 670 or A (alanine) at position 654 is actually responsible for the acquired resistance to imatinib. For both the substitutions, in fact, the phosphorylation of the receptor persisted in the presence of 3 mM of the drug, indicating the occurrence of activated receptors. Interestingly, the single and double mutant V654A appeared to be unphosphorylated and thus inhibited at 6 mM of imatinib, whereas the single and double mutant T670I did not. A reason for this behavior, at a molecular level, can be found in the results obtained from the MD simulations performed on the complex of imatinib with wild-type and both mutated KIT receptors. In fact, the values reported of the difference in the calculated free energies of binding of imatinib and the two mutant proteins clearly suggest that two different mechanisms should underline the lower inhibitor affinity. The DDG bind obtained for the KIT/T670I mutant is -3.84 kcal/mol, suggesting that the replacement of the polar residue T with the neutral I induces a substantial deformation of the binding pocket. Accordingly, the missing hydrogen bond between I670 and imatinib is not the only leading cause for drug binding failure to the protein. In utter analogy with what was observed by us for the homologous residue T315 in the c-ABL kinase domain (Pricl et al., 2005) , this failure instead results from a domino effect induced by the conformational readjustment necessary to accommodate the mutant residue, which involves several other important drug contact points. On the contrary, the smaller DDG bind value obtained for the V654A mutant is in line with a replacement of a hydrophobic residue into another of smaller size. A vast amount of structural data on various mutant proteins from different groups (Matthews, 1993; Buckle et al., 1996; Dwyer et al., 2000; Takano et al., 2001) suggests that single-site amino-acid substitutions, especially in the case of conservative replacements, do not affect the global structure of proteins. In other words, mutant proteins usually retain overall structures that are very similar to those of their wild-type counterparts. In some cases, there are no conformational alterations, and the structure remains completely unchanged. In the rest of the cavity-creating variants, there are some movements in the position of atoms leaning the newly created cavity, but in each case the cavity remained in the structure of the variant. Clearly, this is the case of the KIT/V654A mutant: in this scenario, a 'cavity-creating' amino-acid substitution (V-A) at a largely buried site such as position 654 in KIT does not lead to dramatic structural changes that completely alter or eliminate the cavity, but has an effect only on the structure in the vicinity of the substitution site.
All these observations are in line with our experimental evidences. Interestingly, the V654A mutation was detected in a patient treated with 400 mg/die of imatinib. It would have been appealing to observe the clinical and radiological evolution of this tumor if the patient would have been treated with imatinib at 800 mg/die. Based on our data, in fact, the effect of this mutation might be subverted by a dose escalation of the inhibitor and it would be expected to recapture a clinical response.
Another intriguing aspect that is becoming evident also in the literature (Chen et al., 2004; Tamborini et al., 2004 Tamborini et al., , 2005 Debiec-Rychter et al., 2005; Antonescu et al., 2005; Wardelmann et al., 2005) is why these mutations, T670I and V654A, are detected only in GIST patients who underwent imatinib treatment, whereas others, D820Y and N822K, are not (Debiec-Rychter et al., 2005) . Most likely, the frequency of these mutations is very low and only the selective pressure of the drug is able to make evident the resistant clones.
Surprisingly but perhaps not unexpected, most of the substitutions described affecting KIT receptor are homologous to those described in ABL kinase of chronic myelogenous leukemia (CML) patients. In particular, T670I is homologous to T315I of BCR-ABL detected in some CML patients resistant to imatinib (Deininger et al., 2005) . As they affect the ATP pocket of the kinases, it could be supposed that other molecules could be employed as alternative drugs in a second-line therapy in both the diseases, GIST and CML. An example is represented by two new molecules, AMN107 (Novartis Pharamceuticals, Basel, Swizerland) and BMS-354825 (Brystol Myers Squibb, New York, NY, USA), which are more effective than imatinib in a series of ABL mutants (O'Hare et al., 2005) .
In this light, biochemical analysis on mutated receptors testing the actual imatinib resistance coupled with molecular modeling could be of help in the design of new drugs and this combined approach will give important information to medical oncologist indicating the most suitable dose for escaping secondary resistance.
